What are the differences between minoxidil (topical) and finasteride (oral) in the treatment of androgenetic alopecia?

Minoxidil vs Finasteride for Androgenetic Alopecia

For male androgenetic alopecia, oral finasteride 1 mg/day is more effective than topical minoxidil 5%, with clinical cure rates of 80% versus 52% respectively, though combining both agents yields the best outcomes (94% improvement rate). 1, 2

Mechanism of Action Differences

Minoxidil works through multiple pathways including vasodilation via ATP-sensitive potassium channels, anti-inflammatory effects, Wnt/β-catenin signaling induction, and anagen phase extension. Topical minoxidil requires conversion to its active sulfate form by scalp sulfotransferase enzymes, while oral minoxidil is converted in the liver. 3

Finasteride specifically inhibits 5α-reductase type II enzyme, reducing DHT conversion from testosterone. This directly addresses the hormonal mechanism driving androgenetic alopecia in genetically susceptible individuals. 4

FDA-Approved Indications

Topical Minoxidil

• Men: 5% solution or foam twice daily for vertex baldness 5
• Women: 2% solution twice daily OR 5% foam once daily 3
• Results visible at 2-4 months minimum
• Requires continuous use or hair loss resumes within 3-4 months 5

Oral Finasteride

• Men only: 1 mg/day (FDA-approved)
• Contraindicated in women of childbearing potential due to teratogenicity
• Not approved for women at any dose 1

Comparative Efficacy Data

The efficacy hierarchy based on available evidence:

1. Combination therapy (topical minoxidil + finasteride): 94.1% improvement 2
2. Oral finasteride 1 mg/day: 80% clinical cure rate 1
3. Topical minoxidil 5%: 52-59% improvement 1, 2

Important caveat: Dutasteride 0.5 mg/day (inhibits both 5α-reductase type I and II) appears more effective than finasteride but is not FDA-approved in the US for AGA, though approved in Japan and South Korea. 4, 6

Side Effect Profiles

Minoxidil

• Topical: Contact dermatitis (often from propylene glycol vehicle), scalp irritation, transient shedding (first 2 weeks), unwanted facial/body hair growth 3, 5
• Oral (low-dose 0.25-5 mg/day): Dose-dependent hypertrichosis, cardiovascular symptoms (tachycardia, fluid retention), though serious effects rare at low doses 3, 4
• Systemic absorption from topical application is negligible 3

Finasteride

• Sexual dysfunction: Decreased libido (most common), erectile dysfunction reported in 6-7% of patients 1
• Neuropsychiatric effects: Depression, anxiety (less common)
• Hormonal changes: Decreased serum DHT and PSA, increased total testosterone 1
• All side effects resolve upon discontinuation 1

Clinical Decision Algorithm

For Men with Androgenetic Alopecia:

First-line approach:

• Start with oral finasteride 1 mg/day if no contraindications (cardiovascular disease, desire for fertility in near term)
• Alternative: Topical minoxidil 5% twice daily if patient refuses oral medication or has concerns about sexual side effects

Second-line approach:

• Add the other agent if monotherapy shows inadequate response after 4-6 months
• Combination therapy from the start can be considered for more aggressive treatment, particularly in younger patients with rapid progression 2, 7

Emerging option:

• Low-dose oral minoxidil (0.25-5 mg/day) is increasingly used off-label with promising results, though comparative efficacy data versus topical minoxidil remains limited 3

For Women with Androgenetic Alopecia:

Only option:

• Topical minoxidil (2% twice daily or 5% once daily) 3, 5
• Finasteride is contraindicated in women of childbearing potential
• May consider finasteride in postmenopausal women off-label, though evidence is limited

Critical Monitoring Points

Before Starting Finasteride:

• Baseline PSA (will decrease by ~50%, important for prostate cancer screening)
• Discuss fertility plans (may affect sperm parameters)
• Screen for depression/anxiety history

Before Starting Oral Minoxidil:

• Blood pressure assessment (contraindicated if <90/60 mm Hg) 3
• Cardiac history (contraindication: history of tachycardia, arrhythmia, pericardial effusion) 3
• Renal function (precaution in impairment, contraindication in dialysis patients) 3

Common Pitfalls to Avoid

1. Stopping treatment prematurely: Both agents require 4-6 months minimum for visible results; initial shedding with minoxidil (first 2 weeks) is expected and indicates treatment response 5

2. Discontinuing successful treatment: Hair loss resumes 3-4 months after stopping either medication; this is permanent therapy 5

3. Expecting complete regrowth: Neither agent restores full hair density; realistic expectation is stabilization plus partial regrowth 5

4. Using finasteride in women: Absolutely contraindicated in pregnancy/breastfeeding; even handling crushed tablets poses risk 5

5. Ignoring topical finasteride option: Topical finasteride 0.1-0.25% combined with minoxidil offers similar efficacy to oral finasteride with reduced systemic side effects, though requires twice-daily application 8, 9, 7